NeoGenomics Financials - Benzinga

NeoGenomics Inc

NEONASDAQ

Trade with Public

Trade with Public

$16.42

-0.11-0.67%

At close: Aug 11, 5:00 PM EST

$17.00

0.472.84%

Pre-Market: 3:00 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

NeoGenomics Financials

NeoGenomics (NEO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
NeoGenomics Raises FY2026 Sales Guidance from $797.000M-$803.000M to $802.000M-$806.000M vs $800.433M Est

NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $797.000 million-$803.000 million to $802.000 million-$806.000 million vs $800.433 million estimate.

Benzinga Newsdesk

PRO
NeoGenomics Q2 Adj. EPS $0.05 Beats $0.03 Estimate, Sales $202.000M Beat $196.997M Estimate

NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66.67 percent. This is a 66.67 percent increase over earnings of $0.03 per share from the

Benzinga Newsdesk

Earnings Scheduled For May 12, 2026

Benzinga Insights

PRO
NeoGenomics Raises FY2026 Sales Guidance from $793.000M-$801.000M to $797.000M-$803.000M vs $796.641M Est

NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $793.000 million-$801.000 million to $797.000 million-$803.000 million vs $796.641 million estimate.

Benzinga Newsdesk

PRO
NeoGenomics Q1 Adj. EPS $0.01, Inline, Sales $186.672M Beat $184.509M Estimate

NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. The company reported quarterly sales of $186.672 million which beat the analyst consensus estimate of

Benzinga Newsdesk

Earnings Scheduled For April 28, 2026

Benzinga Insights